This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
binding lectin | 717 |
dendritic cells | 557 |
mbl levels | 505 |
nk cells | 496 |
immune system | 451 |
cell line | 410 |
complement activation | 401 |
peripheral blood | 362 |
immune responses | 350 |
flow cytometry | 341 |
lymph nodes | 335 |
immune response | 324 |
healthy controls | 296 |
iga protease | 273 |
mononuclear cells | 249 |
cell lines | 248 |
cell proliferation | 247 |
amino acid | 245 |
cancer cell | 240 |
iga antibody | 238 |
lectin pathway | 235 |
innate immune | 226 |
inflammatory cytokines | 216 |
blood mononuclear | 215 |
like domain | 207 |
important role | 191 |
blood donors | 175 |
complement system | 173 |
human collectins | 173 |
cellular immune | 173 |
results suggest | 173 |
results indicate | 172 |
oral mucosa | 171 |
proliferating cells | 170 |
cd expression | 170 |
acid bacteria | 167 |
lactic acid | 167 |
activated macrophages | 165 |
alternatively activated | 165 |
tumour cells | 165 |
pattern recognition | 164 |
mbl gene | 160 |
present study | 158 |
cell responses | 154 |
significantly higher | 152 |
surfactant protein | 150 |
necrosis factor | 149 |
high mbl | 147 |
healthy individuals | 140 |
ex vivo | 139 |
protease activity | 139 |
serum mbl | 138 |
whole blood | 137 |
ear skin | 137 |
multiple sclerosis | 137 |
blood samples | 137 |
breast cancer | 137 |
humoural responses | 137 |
tumour necrosis | 137 |
corresponding hc | 136 |
dc maturation | 136 |
type i | 136 |
lactobacillus spp | 136 |
control donors | 136 |
patients receiving | 136 |
autologous bacteria | 136 |
cells may | 135 |
cell death | 135 |
gut flora | 134 |
ifn species | 134 |
may therefore | 134 |
peptide antigens | 133 |
proteome analysis | 133 |
mice immunized | 133 |
sentinel lymph | 132 |
mhc i | 132 |
intracellular ifn | 132 |
related lipoproteins | 132 |
lactobacillus acidophilus | 132 |
binding assays | 132 |
mbl genotypes | 130 |
mbl deficiency | 126 |
serine proteases | 122 |
complement activity | 119 |
adaptive immunity | 117 |
cytokine production | 116 |
inflammatory response | 113 |
binding protein | 113 |
mbl masp | 111 |
monoclonal antibody | 111 |
virus infection | 111 |
type ii | 110 |
colorectal cancer | 109 |
associated serine | 109 |
increased levels | 109 |
natural killer | 106 |
cell response | 106 |
chronic inflammatory | 105 |
bronchial asthma | 105 |
binding site | 105 |
sendai virus | 105 |
allergic rhinitis | 105 |
type lectins | 104 |
healthy blood | 104 |
serine protease | 104 |
dna vaccination | 104 |
dairy cows | 103 |
clonally expanded | 103 |
oral carcinoma | 103 |
iga antibodies | 103 |
specific cd | 103 |
mbl double | 103 |
type ifn | 102 |
genes involved | 102 |
normal mucosa | 102 |
dna vaccine | 102 |
target bacteria | 102 |
currently investigating | 102 |
ms patients | 102 |
weak il | 102 |
analysed using | 102 |
pss patients | 102 |
ectopic gc | 102 |
findings indicate | 101 |
pivotal role | 101 |
th phenotype | 101 |
time points | 101 |
vitro stimulation | 101 |
special emphasis | 101 |
sequence homology | 101 |
mg ml | 101 |
human recombinant | 100 |
protein microarrays | 100 |
macrophage galactose | 100 |
time pcr | 100 |
surface markers | 100 |
human blood | 100 |
alveolar macrophages | 100 |
cell cytotoxicity | 100 |
cytokine tumour | 100 |
global proteome | 100 |
growth factor | 100 |
clinical use | 100 |
results will | 100 |
hla supertypes | 99 |
response towards | 99 |
antibody microarrays | 99 |
tumour cell | 99 |
bacterial antigen | 99 |
bacteria lactobacillus | 99 |
transduced eph | 99 |
database system | 99 |
i molecules | 99 |
cell reactivity | 99 |
bioinformatics tools | 99 |
binding regions | 99 |
mbl ko | 96 |
apoptotic cells | 91 |
influenza virus | 90 |
ng ml | 87 |
cell activation | 85 |
recognition molecule | 84 |
mouse model | 83 |
activate complement | 82 |
significantly increased | 81 |
innate immunity | 81 |
immune complexes | 79 |
nucleotide polymorphisms | 79 |
acute respiratory | 79 |
single nucleotide | 79 |
recognition molecules | 79 |
nonstructural protein | 78 |
gene expression | 78 |
complement components | 78 |
recombinant human | 77 |
mbl concentration | 77 |
antiviral activity | 76 |
critical role | 76 |
mbl pathway | 76 |
binding proteins | 76 |
high levels | 75 |
escherichia coli | 75 |
nitric oxide | 74 |
lower levels | 74 |
receptor expression | 74 |
human peripheral | 74 |
lectin gene | 74 |
acid residues | 73 |
negative bacteria | 73 |
control group | 73 |
microbial surfaces | 73 |
normal human | 73 |
specific antibodies | 73 |
target cells | 73 |
type diabetes | 73 |
cytokine responses | 72 |
virus nonstructural | 72 |
vascular complications | 72 |
th th | 72 |
pylori infection | 71 |
patients compared | 71 |
inflammatory cytokine | 71 |
airway inflammation | 71 |
cell surface | 71 |
mammalian cells | 71 |
severe acute | 71 |
cancer patients | 71 |
blood cells | 71 |
cell subsets | 71 |
cancer cells | 70 |
crystal structure | 70 |
antibodies specific | 70 |
respiratory syndrome | 70 |
killer cell | 70 |
mrna expression | 70 |
plasmodium falciparum | 70 |
dust mite | 70 |
major role | 70 |
regional lymph | 69 |
regression analysis | 69 |
human monoclonal | 69 |
contact sensitivity | 69 |
igg antibodies | 69 |
allergic airway | 69 |
healthy volunteers | 69 |
mt cells | 69 |
found among | 69 |
related molecules | 69 |
heat shock | 69 |
lcm virus | 69 |
may help | 69 |
commensal bacteria | 69 |
class i | 69 |
mt mt | 69 |
vascular endothelial | 69 |
coli lps | 68 |
responsiveness ex | 68 |
fluticasone propionate | 68 |
peptide mapping | 68 |
solid supports | 68 |
cysteine protease | 68 |
recently identified | 68 |
surface expression | 68 |
subsequent development | 68 |
cells decreased | 68 |
gastric juice | 68 |
ingested probiotics | 68 |
normal colon | 68 |
protein microarray | 68 |
mt ratio | 68 |
peptides spanning | 68 |
final visit | 68 |
patients presented | 68 |
cytotoxicity increased | 68 |
healthy donors | 68 |
large panel | 68 |
dm patients | 68 |
pressurized chamber | 68 |
low mbl | 68 |
aureus serotypes | 68 |
double ko | 68 |
lymph node | 68 |
ko animals | 68 |
cytokine profile | 68 |
persons working | 68 |
results showed | 68 |
macrovascular complications | 68 |
bacterial strains | 68 |
carcinoma cell | 68 |
hyperbaric exposure | 68 |
mt phenotype | 68 |
dietary vitamin | 68 |
cd ra | 68 |
protected rats | 68 |
studies will | 68 |
cancer treatment | 68 |
normoalbuminuric group | 68 |
pneumoniae serotypes | 68 |
dna construct | 68 |
rantes expression | 68 |
noise threshold | 68 |
human mnsod | 68 |
focus score | 68 |
adaptor molecules | 68 |
rhamnosus gg | 68 |
maturation markers | 68 |
human gut | 68 |
colon mucosa | 68 |
fusion proteins | 68 |
weeks post | 68 |
pylori igg | 68 |
recall stimulation | 68 |
preliminary results | 68 |
including ingested | 68 |
ics alone | 68 |
control animals | 68 |
white blood | 68 |
five putative | 68 |
tlr adaptor | 68 |
igg caga | 68 |
low tnf | 68 |
derived peptides | 68 |
malarial antigen | 68 |
lactobacillus rhamnosus | 68 |
currently trying | 68 |
eae induction | 68 |
seroimmunological phenotype | 68 |
bifidobacterium spp | 68 |
university hospital | 68 |
sows fed | 68 |
immature dcs | 67 |
using flow | 67 |
mediated opsonophagocytosis | 67 |
herpes simplex | 67 |
immunomodulatory therapies | 67 |
terminal part | 67 |
postoperative infections | 67 |
micro flora | 67 |
cell epitopes | 67 |
zone macrophages | 67 |
masp activity | 67 |
will address | 67 |
assays require | 67 |
serum resistance | 67 |
less pronounced | 67 |
assay using | 67 |
feedback regulation | 67 |
antiviral neutralization | 67 |
clinical signs | 67 |
marginal zone | 67 |
pulmonary tb | 67 |
specific cytotoxic | 67 |
cell cycle | 67 |
bacterial stimulation | 67 |
costimulatory molecule | 67 |
single amino | 67 |
mblassociated serine | 67 |
ifn biologicals | 67 |
cell layer | 67 |
negative feedback | 67 |
commercially available | 67 |
high amounts | 67 |
different time | 67 |
simplex virus | 67 |
monitor patients | 67 |
carried using | 67 |
laborious titrations | 67 |
antibody fragments | 67 |
cytokines il | 67 |
inflammatory effects | 67 |
require laborious | 67 |
protein content | 67 |
potentially immunogenic | 67 |
bioavailability varies | 67 |
nk cell | 67 |
titrations making | 67 |
increasingly used | 67 |
better reporter | 67 |
microarrays will | 66 |
activate nk | 66 |
svegfr release | 66 |
interaction chromatography | 66 |
activation state | 66 |
lymphocyteassociated antigen | 66 |
blood leucocytes | 66 |
highthroughput global | 66 |
tumour extract | 66 |
macrophages elicited | 66 |
induced rantes | 66 |
significant increase | 66 |
nonsentinel lymph | 66 |
acid substitution | 66 |
specific nucleotidyl | 66 |
allergen carriers | 66 |
major source | 66 |
ctl activity | 66 |
mammalian cytokine | 66 |
endothelial growth | 66 |
release assay | 66 |
plasma svegf | 66 |
generation anns | 66 |
hydrophobic interaction | 66 |
stranded rna | 66 |
predicted binding | 66 |
mbp antibodies | 66 |
laboratory notebooks | 66 |
ii cytokine | 66 |
standard operating | 66 |
type lectin | 66 |
unique possibility | 66 |
preoperative mbl | 66 |
containing ic | 66 |
affect nk | 66 |
increased risk | 66 |
type cytokines | 66 |
bladder cancer | 66 |
membrane depolarization | 66 |
molecular markers | 66 |
versus mg | 66 |
cutaneous lymphocyteassociated | 66 |
novel allergen | 66 |
novel markers | 66 |
peptide ligands | 66 |
inducible costimulator | 66 |
unstimulated cd | 66 |
different lab | 66 |
reactive lymphocytes | 66 |
cell count | 66 |
transduced cell | 66 |
cd bright | 66 |
will allow | 66 |
svegfr concentrations | 66 |
ae sem | 66 |
results demonstrate | 66 |
psoriatic skin | 66 |
variant tumour | 66 |
induced release | 66 |
operating procedures | 66 |
homing cutaneous | 66 |
scale clinical | 66 |
database solution | 66 |
soluble vascular | 66 |
qbc peptides | 66 |
sentinel nodes | 66 |
epithelial cell | 66 |
immunized mice | 66 |
boost vaccinations | 66 |
children living | 66 |
ficolin ml | 66 |
oligoadenylate synthetases | 66 |
laboratory information | 66 |
obtain tumour | 66 |
derived antigens | 66 |
viral infection | 66 |
hyperimmunized mice | 66 |
peptide epitopes | 66 |
hla supertype | 66 |
splenic cd | 66 |
cytokine environment | 66 |
predisposing factor | 66 |
qbc experiment | 66 |
enriched ann | 66 |
mg bd | 66 |
invertebrate pattern | 66 |
intercellular contact | 66 |
induced complement | 66 |
sarcoid origin | 66 |
rich data | 66 |
tcr vb | 66 |
protease domains | 66 |
antitumour response | 66 |
mbl may | 64 |
alternative pathway | 63 |
mannose binding | 63 |
infected cells | 63 |
disease severity | 60 |
increased susceptibility | 59 |
systemic lupus | 58 |
lupus erythematosus | 58 |
low levels | 57 |
wt mice | 54 |
mbl concentrations | 54 |
mbl binds | 54 |
risk factor | 53 |
staphylococcus aureus | 53 |
vaccinia virus | 52 |
epithelial cells | 52 |
mbl genotype | 52 |
treatment group | 51 |
statistically significant | 51 |
serum mannose | 50 |
cord uid | 50 |
doc id | 50 |
host defense | 49 |
septic shock | 49 |
inflammatory responses | 49 |
may also | 48 |
significantly lower | 48 |
rat serum | 48 |
monoclonal antibodies | 47 |
proinflammatory cytokines | 47 |
antibody response | 47 |
gene polymorphisms | 47 |
endothelial cells | 47 |
also found | 46 |
like receptor | 46 |
infected patients | 46 |
acute phase | 46 |
immune cells | 45 |
rheumatoid arthritis | 45 |
complement pathway | 45 |
proinflammatory cytokine | 45 |
mannose receptor | 45 |
cov infection | 45 |
levels may | 45 |
linked glycosylation | 44 |
activation via | 44 |
clinical studies | 44 |
complement pathways | 44 |
recognition receptors | 43 |
human dendritic | 43 |
higher levels | 43 |
odds ratio | 43 |
control subjects | 43 |
serum samples | 43 |
mycobacterium tuberculosis | 42 |
bone marrow | 42 |
data suggest | 42 |
antibody responses | 42 |
mbl plays | 42 |
stem cell | 42 |
may play | 41 |
higher risk | 41 |
complement factor | 41 |
pseudomonas aeruginosa | 41 |
first line | 41 |
histamine release | 41 |
like receptors | 41 |
performed using | 41 |
trypanosoma cruzi | 40 |
cytokine response | 40 |
serum levels | 40 |
significantly associated | 40 |
derived dendritic | 40 |
nervous system | 40 |
recent studies | 40 |
autoimmune diseases | 40 |
glycosylation site | 40 |
higher mbl | 40 |
central nervous | 40 |
may influence | 39 |
possible role | 39 |
helicobacter pylori | 39 |
taken together | 39 |
phase reactant | 39 |
antigen presentation | 39 |
inflammatory diseases | 39 |
diabetic patients | 39 |
apoptotic cell | 39 |
inflammatory mediators | 39 |
independent manner | 39 |
investigated whether | 39 |
immune status | 38 |
protective effect | 38 |
acquired immunity | 38 |
findings suggest | 38 |
mice compared | 38 |
increased expression | 38 |
presenting cells | 38 |
mbl status | 38 |
functional mbl | 38 |
low expression | 38 |
mannosebinding lectin | 38 |
colorectal carcinoma | 38 |
igm responses | 38 |
directed mutagenesis | 38 |
altered self | 38 |
responses following | 38 |
intensive care | 38 |
myeloid cells | 38 |
carbohydrate structures | 38 |
surface antigen | 38 |
flow cytometric | 38 |
mediated immune | 37 |
genes encoding | 37 |
direct effect | 37 |
occurs via | 37 |
key role | 37 |
regulatory role | 37 |
exon encodes | 37 |
salivary gland | 37 |
randomly selected | 37 |
compared using | 37 |
physiological conditions | 37 |
type diabetic | 37 |
following acute | 37 |
large number | 37 |
like activity | 37 |
hbv infection | 37 |
two types | 37 |
also play | 37 |
plasma samples | 37 |
higher incidence | 37 |
closely related | 37 |
environmental factors | 37 |
studies involving | 37 |
using elisa | 37 |
fusion protein | 37 |
high degree | 37 |
mast cell | 37 |
th responses | 37 |
significantly elevated | 37 |
increased mbl | 37 |
diabetic nephropathy | 37 |
studies revealed | 37 |
complement factors | 37 |
lymphocytic choriomeningitis | 37 |
specific primers | 37 |
cardiovascular disease | 37 |
signal transduction | 37 |
complement inhibitor | 37 |
th response | 37 |
carcinoma cells | 37 |
western blotting | 37 |
serum albumin | 37 |
mbl ml | 37 |
much higher | 37 |
specific igm | 37 |
previously reported | 37 |
infection may | 37 |
sequence similarity | 36 |
genetic background | 36 |
cell types | 36 |
studies suggested | 36 |
study included | 36 |
nude mice | 36 |
positive bacteria | 36 |
hepatocellular carcinoma | 36 |
two different | 36 |
may provide | 36 |
gene products | 36 |
statistically analysed | 36 |
increased production | 36 |
similar effect | 36 |
cellular response | 36 |
clinical data | 36 |
higher level | 36 |
wildtype mice | 36 |
human disease | 36 |
also inhibit | 36 |
determine whether | 36 |
specific ige | 36 |
cell receptor | 36 |
tlr expression | 36 |
human monocytes | 36 |
biotinylated anti | 36 |
induced il | 36 |
poor prognosis | 36 |
small size | 36 |
times higher | 36 |
demonstrate binding | 36 |
house dust | 36 |
different groups | 36 |
complement resistance | 36 |
expression profiles | 36 |
control groups | 36 |
monocytic cell | 36 |
one study | 36 |
also capable | 36 |
directly interact | 36 |
almost exclusively | 36 |
also used | 36 |
higher concentration | 36 |
patient groups | 36 |
cells express | 36 |
whereas others | 36 |
central role | 36 |
lung function | 36 |
important implications | 36 |
human factor | 36 |
fully understood | 36 |
oxide production | 36 |
considered statistically | 36 |
still unclear | 36 |
terminal amino | 36 |
manganese superoxide | 35 |
mucosal sites | 35 |
greater effect | 35 |
human colon | 35 |
cell differentiation | 35 |
recently reported | 35 |
human parvovirus | 35 |
might result | 35 |
myelin basic | 35 |
experimental autoimmune | 35 |
acute infection | 35 |
investigate whether | 35 |
activated complement | 35 |
longitudinal study | 35 |
assay described | 35 |
macrophage mannose | 35 |
five patients | 35 |
prospective studies | 35 |
proteins may | 35 |
specific marker | 35 |
positive cells | 35 |
exact role | 35 |
activity may | 35 |
proteins showed | 35 |
adjuvant effect | 35 |
human populations | 35 |
acid sphingomyelinase | 35 |
buffered saline | 35 |
borrelia garinii | 35 |
future studies | 35 |
cytokine secretion | 35 |
clinical context | 35 |
reduced expansion | 35 |
newly emerged | 35 |
culture supernatants | 35 |
syndrome coronavirus | 35 |
evidence indicates | 35 |
induced inflammatory | 35 |
inflammatory disease | 35 |
transcription factor | 35 |
costimulatory molecules | 35 |
macrophage inflammatory | 35 |
detected among | 35 |
expanded cd | 35 |
different diseases | 35 |
acute viral | 35 |
previously demonstrated | 35 |
seven times | 35 |
individual patients | 35 |
genetic predisposition | 35 |
chemokine expression | 35 |
derived dcs | 35 |
combined studies | 35 |
vascular endothelium | 35 |
monocytes differentiate | 35 |
studied whether | 35 |
cutaneous lymphocyte | 35 |
tested positive | 35 |
tissue sections | 35 |
cell functions | 35 |
epitope specificity | 35 |
borrelia burgdorferi | 35 |
mbl complexes | 35 |
even lower | 35 |
mononuclear phagocytes | 35 |
developed using | 35 |
potential risk | 35 |
bind factor | 35 |
different antigens | 35 |
many countries | 35 |
superoxide dismutase | 35 |
mass spectrometry | 35 |
also expressed | 35 |
readily detectable | 35 |
two additional | 35 |
may potentially | 35 |
elevated mbl | 35 |
purification procedure | 35 |
probiotic bacteria | 35 |
protease inhibitor | 35 |
linked immunosorbent | 35 |
low level | 35 |
cells within | 35 |
exon alleles | 35 |
embedded tissue | 35 |
gel electrophoresis | 35 |
signal peptide | 35 |
cells showed | 35 |
autoimmune encephalomyelitis | 35 |
putative mbl | 35 |
basic protein | 35 |
protein production | 35 |
parallel experiment | 35 |
coli infections | 35 |
malassezia sympodialis | 35 |
mediated immunity | 35 |
renal disease | 35 |
median serum | 35 |
permeation chromatography | 35 |
memory response | 35 |
capsular polysaccharide | 35 |
inflammatory gene | 35 |
cells increased | 35 |
rna isolated | 35 |
increased cd | 35 |
infectious complications | 35 |
protective dna | 35 |
regression model | 35 |
times lower | 35 |
direct effects | 35 |
patients showed | 35 |
female patients | 35 |
autoantibody production | 35 |
part mediated | 35 |
immune modulation | 35 |
exclusively expressed | 35 |
found mainly | 35 |
asthmatic patients | 35 |
protein induced | 35 |
blood stem | 35 |
may allow | 35 |
two patients | 35 |
largely unknown | 35 |
venous blood | 35 |
may cause | 35 |
gastric mucosa | 35 |
gel permeation | 35 |
effects observed | 35 |
cell mediated | 35 |
bowel disease | 35 |
related proteins | 35 |
will also | 35 |
healthy control | 35 |
overt nephropathy | 35 |
inflammatory bowel | 35 |
class ii | 35 |
sympodialis allergen | 35 |
indian origin | 34 |
cytolytic activity | 34 |
low tlr | 34 |
novozymes focuses | 34 |
myd totally | 34 |
mutation strategy | 34 |
decreased antibody | 34 |
appropriate adjuvant | 34 |
plasmon resonance | 34 |
clonal deletion | 34 |
probes retained | 34 |
nonradioactive proliferation | 34 |
phagosomal degradation | 34 |
secondary antibody | 34 |
induced cd | 34 |
activities makes | 34 |
morphologically screened | 34 |
using gene | 34 |
leukaemia relapse | 34 |
without vascular | 34 |
also potentiated | 34 |
million people | 34 |
lower dose | 34 |
exp clin | 34 |
proteins elicited | 34 |
control diet | 34 |
hypoallergenic variants | 34 |
interesting due | 34 |
molecules expressed | 34 |
responses target | 34 |
lymphocyte infiltration | 34 |
allergic asthma | 34 |
estrogen receptor | 34 |
burgdorferi strains | 34 |
probiotics mainly | 34 |
esrd patients | 34 |
primary function | 34 |
coli infection | 34 |
thereby becoming | 34 |
direct measurenment | 34 |
patients experiencing | 34 |
gradient gel | 34 |
used flow | 34 |
kg animal | 34 |
mucosa samples | 34 |
patch tests | 34 |
pronounced differences | 34 |
viral origin | 34 |
microarray applications | 34 |
whereas ldh | 34 |
production induced | 34 |
mnsod needs | 34 |
i allergen | 34 |
reported sparing | 34 |
significant pathology | 34 |
covalent coupling | 34 |
periodic haemodialysis | 34 |
liver cirrhosis | 34 |
cells consecutively | 34 |
general hospital | 34 |
high demands | 34 |
strong specific | 34 |
nonlymphoid cells | 34 |
denaturing gradient | 34 |
cytokine levels | 34 |
constructed around | 34 |
recognize molecular | 34 |
inflammatory mechanisms | 34 |
pigs often | 34 |
new vaccines | 34 |
require confirmation | 34 |
one piglet | 34 |
gained increasing | 34 |
higher opsonophagocytosis | 34 |
whole lymph | 34 |
gut dc | 34 |
ospe sequences | 34 |
response revealed | 34 |
unsensitized animals | 34 |
gut microbes | 34 |
important members | 34 |
surface plasmon | 34 |
subsequent eae | 34 |
igg compared | 34 |
clin immunogenet | 34 |
fed increasing | 34 |
hdm extracts | 34 |
identified five | 34 |
associated macrovascular | 34 |
pools throughout | 34 |
complex mixtures | 34 |
basal cell | 34 |
novel molecule | 34 |
also indicated | 34 |
blood sampling | 34 |
unlike cla | 34 |
treg cell | 34 |
secondary memory | 34 |
spontaneous cytotoxicity | 34 |
expression mbl | 34 |
microarray requires | 34 |
similar patterns | 34 |
visits every | 34 |
normal gastrointestinal | 34 |
ige epitopes | 34 |
eight persons | 34 |
mrna levels | 34 |
gastrointestinal flora | 34 |
soluble antigens | 34 |
antibody extracted | 34 |
elicit specific | 34 |
mice bearing | 34 |
obtain nearly | 34 |
nephropathy status | 34 |
unstimulated human | 34 |
dialysis group | 34 |
upregulating surface | 34 |
consistently low | 34 |
regulate mucosal | 34 |
human lung | 34 |
stimulation weeks | 34 |
cytotoxicity observed | 34 |
exacerbation may | 34 |
persistent normoalbuminuria | 34 |
fca receptor | 34 |
whether vitamin | 34 |
relapse compared | 34 |
specifically bind | 34 |
immunity via | 34 |
total igg | 34 |
binding efficiency | 34 |
sfc million | 34 |
components like | 34 |
priming effect | 34 |
strongly inhibited | 34 |
week intervals | 34 |
carcinoma line | 34 |
overlapping peptides | 34 |
burgdorferi sensu | 34 |
mddcs exposed | 34 |
mammalian cell | 34 |
wt controls | 34 |
kos mounted | 34 |
achieved mainly | 34 |
mixtures occasionally | 34 |
noncapsulated variants | 34 |
sparing action | 34 |
produce iga | 34 |
evolutionary conserved | 34 |
via putative | 34 |
potential cross | 34 |
leica light | 34 |
putative regions | 34 |
subsequent binding | 34 |
strong cytokine | 34 |
nonmyeloablative conditioning | 34 |
cellular stress | 34 |
nonpurified probes | 34 |
predicted epitopes | 34 |
higher productions | 34 |
hsp primes | 34 |
upper airways | 34 |
serum lysis | 34 |
proteases like | 34 |
elisa technique | 34 |
thereby enhance | 34 |
alternative activation | 34 |
receiving ics | 34 |
foreign antigen | 34 |
glycosylated soluble | 34 |
different molecular | 34 |
strong th | 34 |
possible feeding | 34 |
positively charged | 34 |
binding region | 34 |
remain largely | 34 |
differentially dc | 34 |
minor salivary | 34 |
removed one | 34 |
humoural immunity | 34 |
variants may | 34 |
experiencing graft | 34 |
pneumococcal capsular | 34 |
cytokine strongly | 34 |
cd epitopes | 34 |
sensitive detection | 34 |
inducible expression | 34 |
spirochetes utilize | 34 |
recombinant variant | 34 |
receptor clonotype | 34 |
measurable proliferation | 34 |
levels independently | 34 |
dna motifs | 34 |
dth response | 34 |
eight divers | 34 |
induced macrophage | 34 |
probiotic gram | 34 |
peptide mog | 34 |
studied lxrs | 34 |
experimental physiological | 34 |
surface design | 34 |
investigated il | 34 |
responsiveness via | 34 |
wt control | 34 |
shock protein | 34 |
inhaled long | 34 |
fed either | 34 |
ko phenotype | 34 |
immunostimulatory effects | 34 |
adjuvant properties | 34 |
hsp molecule | 34 |
represents one | 34 |
important part | 34 |
bifidobacteria tended | 34 |
human lactobacillus | 34 |
high dietary | 34 |
clonotypes emerged | 34 |
clinic visits | 34 |
position showed | 34 |
especially attracted | 34 |
falciparum hsp | 34 |
animals exhibited | 34 |
nephropathy group | 34 |
decreased weeks | 34 |
phenotype may | 34 |
increased cytotoxicity | 34 |
deficient compared | 34 |
cytometry offers | 34 |
dietary level | 34 |
partially prevented | 34 |
studied simultaneous | 34 |
asmase suggest | 34 |
elicitation locally | 34 |
around calving | 34 |
excellent functional | 34 |
inhaled corticosteroid | 34 |
normally causing | 34 |
without diabetic | 34 |
untreated relapsing | 34 |
working outside | 34 |
autologous bacterial | 34 |
also evaluated | 34 |
like microorganisms | 34 |
address whether | 34 |
exon variant | 34 |
protects lew | 34 |
stabile physiological | 34 |
technology will | 34 |
proliferation phases | 34 |
increasing dietary | 34 |
different serotypes | 34 |
reconstitution experiments | 34 |
received peripheral | 34 |
used bromodeoxyuridin | 34 |
unstimulated phagocytes | 34 |
periparturient period | 34 |
secondary ss | 34 |
directly designed | 34 |
lipoproteins related | 34 |
type immune | 34 |
dna constructs | 34 |
streptococcal pyrogenic | 34 |
salivary adenocarcinoma | 34 |
immunologic similarity | 34 |
increasing interest | 34 |
investigating whether | 34 |
mammalian host | 34 |
escape iga | 34 |
cd adim | 34 |
systemic immunity | 34 |
increasing urea | 34 |
immune reaction | 34 |
current standard | 34 |
cells circulating | 34 |
antigen fused | 34 |
dramatically changes | 34 |
cleaves human | 34 |
mechanisms behind | 34 |
colon cancer | 34 |
antibody library | 34 |
allergen extracts | 34 |
skin prick | 34 |
production remained | 34 |
prevented sendai | 34 |
experiments showed | 34 |
haemodialysis treatment | 34 |
dcs secreted | 34 |
expanded cells | 34 |
per kg | 34 |
transforming growth | 34 |
molecular weight | 34 |
increasing age | 34 |
emerged clonotypes | 34 |
germinal centers | 34 |
large amounts | 34 |
auricular lymph | 34 |
nerve fibre | 34 |
collected immediately | 34 |
eicosanoid synthesis | 34 |
binding motif | 34 |
lactobacillus plantarum | 34 |
interactions trigger | 34 |
juice urea | 34 |
surprisingly narrow | 34 |
hyperbaric setup | 34 |
immunomodulatory effect | 34 |
protease der | 34 |
strains correlated | 34 |
gut mucosa | 34 |
potential exists | 34 |
important regulator | 34 |
lower prostaglandin | 34 |
murine dc | 34 |
weeks close | 34 |
focal infiltration | 34 |
mounted dramatically | 34 |
mammary gland | 34 |
target recognition | 34 |
phagocytotic uptake | 34 |
ubiquitous pathogen | 34 |
allowing nonpurified | 34 |
also exposed | 34 |
proinflammatory chemokines | 34 |
certain microbial | 34 |
colon samples | 34 |
pbmc estimated | 34 |
induced regulatory | 34 |
histological picture | 34 |
highly significant | 34 |
experimental hyperbaric | 34 |
microorganisms seems | 34 |
ingest iga | 34 |
secreted recombinant | 34 |
bacteria dramatically | 34 |
partially rescued | 34 |
regulatory phenotype | 34 |
affinity coupling | 34 |
mbl receptors | 34 |
observed reduction | 34 |
atopy patch | 34 |
herpesvirus herpes | 34 |
imminent exacerbation | 34 |
absolute signal | 34 |
supplementation increased | 34 |
technique involving | 34 |
completely abrogated | 34 |
moderate increase | 34 |
mapping based | 34 |
molecule ceramide | 34 |
first evaluated | 34 |
curative action | 34 |
model system | 34 |
classical activation | 34 |
inflammatory signal | 34 |
dermatophagoides pteronyssinus | 34 |
bacteria escape | 34 |
receptors seem | 34 |
million pbmcs | 34 |
glycoprotein antigens | 34 |
cell directly | 34 |
protein engineering | 34 |
surviving bacteria | 34 |
zeptomole range | 34 |
different tlr | 34 |
complement killing | 34 |
clonotypes persisted | 34 |
whether il | 34 |
ectopic germinal | 34 |
initiated activation | 34 |
dna laddering | 34 |
phenotype represents | 34 |
splenocytes early | 34 |
crc specimens | 34 |
cytokines increased | 34 |
experience gvhd | 34 |
scattered proliferating | 34 |
thereby allowing | 34 |
maturation marker | 34 |
inhibit factor | 34 |
population upregulating | 34 |
increased significantly | 34 |
lectinassociated serine | 34 |
framework displayed | 34 |
laba may | 34 |
fev values | 34 |
whole hsp | 34 |
proteolytic cleavage | 34 |
bead array | 34 |
mice demonstrate | 34 |
candidate autoantigen | 34 |
mxa level | 34 |
simultaneous upregulation | 34 |
probiotic strains | 34 |
affect humoural | 34 |
program analysis | 34 |
complete molecules | 34 |
whether gc | 34 |
factors like | 34 |
stronger secretion | 34 |
perform sensitive | 34 |
blood monocytes | 34 |
fine mapping | 34 |
four different | 34 |
induce interleukin | 34 |
severely impaired | 34 |
remains obscure | 34 |
donors grown | 34 |
recombinant form | 34 |
using cytokine | 34 |
cancer immunotherapy | 34 |
immununized mice | 34 |
stimulate expression | 34 |
eight healthy | 34 |
pyrogenic exotoxin | 34 |
receiving nonmanipulated | 34 |
key transcriptional | 34 |
capsid proteins | 34 |
attracted attention | 34 |
tunel assays | 34 |
otherwise lethal | 34 |
percent eosinophilia | 34 |
differences among | 34 |
bearing salivary | 34 |
immune dysregulation | 34 |
heterogeneous proteins | 34 |
weeks fed | 34 |
initial epitope | 34 |
fourfold higher | 34 |
induced better | 34 |
equally well | 34 |
clinical malaria | 34 |
suppressor cells | 34 |
garinii strains | 34 |
major human | 34 |
handled differently | 34 |
efficient opsonins | 34 |
antibodies along | 34 |
expression occurs | 34 |
phagolysosomally localized | 34 |
least months | 34 |
mhc class | 34 |
purified monocytes | 34 |
iga molecules | 34 |
promote cell | 34 |
strains belonging | 34 |
blood stimulation | 34 |
different peptide | 34 |
investigated immunological | 34 |
receiving laba | 34 |
mouse factor | 34 |
first step | 34 |
several approximately | 34 |
time periods | 34 |
dietary treatment | 34 |
dna vaccinaton | 34 |
virus utilizes | 34 |
cofactor increase | 34 |
involving macrophages | 34 |
five snps | 34 |
gland tissue | 34 |
countries today | 34 |
recently demonstrated | 34 |
stable asthmatics | 34 |
lps also | 34 |
stimulation conditions | 34 |
proliferation assays | 34 |
express il | 34 |
nonmanipulated bmt | 34 |
following weeks | 34 |
ii expression | 34 |
therefore examined | 34 |
streptococcus pneumonia | 34 |
clinical markers | 34 |
allergic reactions | 34 |
anticancer mechanisms | 34 |
greatest capacity | 34 |
controlled based | 34 |
microbial components | 34 |
framework antibody | 34 |
normobar atmosphere | 34 |
crc patients | 34 |
people worldwide | 34 |
molecules trif | 34 |
induced chemokine | 34 |
distinct possibility | 34 |
collected seven | 34 |
turn results | 34 |
position leading | 34 |
lower surface | 34 |
protease deficient | 34 |
inflammatory skin | 34 |
receptor signalling | 34 |
ifn added | 34 |
followed consecutively | 34 |
quantitated using | 34 |
cytotoxic cd | 34 |
increased humoural | 34 |
three proteins | 34 |
yeast malassezia | 34 |
isogenic serotype | 34 |
examined cytokine | 34 |
appreciable levels | 34 |
statistical tools | 34 |
th effector | 34 |
proteins using | 34 |
phagocytes express | 34 |
proliferation may | 34 |
found fhr | 34 |
suppressed cla | 34 |
acutely infected | 34 |
cell replication | 34 |
tlr involved | 34 |
antigen eb | 34 |
limiting disease | 34 |
microarray setup | 34 |
otherwise strong | 34 |
mediated anti | 34 |
study suggest | 34 |
molecules cd | 34 |
offer asthma | 34 |
chimeric dna | 34 |
critical low | 34 |
peptide pools | 34 |
definite ms | 34 |
recombinant mala | 34 |
polysaccharide displayed | 34 |
important regulators | 34 |
physiological periods | 34 |
expression pattern | 34 |
piglet per | 34 |
although international | 34 |
clonotype mapping | 34 |
vastly predominant | 34 |
protease domain | 34 |
vivo ifn | 34 |
commensal intestinal | 34 |
cells might | 34 |
nab activity | 34 |
whereas sendai | 34 |
mitochondrial enzyme | 34 |
approximately kda | 34 |
adjuvant potential | 34 |
pure der | 34 |
inflammatory cells | 34 |
cell balance | 34 |
volunteers using | 34 |
colorectal carcinomas | 34 |
induction inhibited | 34 |
elevated anti | 34 |
mice fail | 34 |
microarray technology | 34 |
available supports | 34 |
mean tnf | 34 |
colonic biopsies | 34 |
basophile histamine | 34 |
utilize analogous | 34 |
novel affinity | 34 |
molecules involved | 34 |
specific immune | 34 |
demyelinating disease | 34 |
increased relatively | 34 |
among carriers | 34 |
safer alternative | 34 |
feeding strategy | 34 |
proteases mannan | 34 |
produced higher | 34 |
aarhus university | 34 |
several months | 34 |
skin disease | 34 |
found frequently | 34 |
tumour regression | 34 |
clinical trial | 34 |
including rheumatoid | 34 |
recombinant pro | 34 |
localized acid | 34 |
ifn bioactivity | 34 |
complexes inhibit | 34 |
tick vector | 34 |
marker cd | 34 |
single microarray | 34 |
numerically higher | 34 |
obtained weekly | 34 |
local autoantibody | 34 |
rmbl partially | 34 |
fibre myelin | 34 |
points analysed | 34 |
occasionally resulting | 34 |
leaves iga | 34 |
whether high | 34 |
displayed excellent | 34 |
humeral immunity | 34 |
microarrays offer | 34 |
better stimulation | 34 |
human il | 34 |
novel major | 34 |
coupling strategies | 34 |
recombinant fusion | 34 |
lower cyclooxygenase | 34 |
arrayed dehydrated | 34 |
atopic eczema | 34 |
asthma control | 34 |
using mutagenesis | 34 |
trigger activation | 34 |
normoalbuminuria matched | 34 |
mammalian infection | 34 |
shock proteins | 34 |
different bacterial | 34 |
induce apoptotic | 34 |
may become | 34 |
receptor heterodimers | 34 |
molecule rat | 34 |
findings identify | 34 |
higher blood | 34 |
hypothetically reflect | 34 |
considerable less | 34 |
deglycosylated pro | 34 |
second class | 34 |
antagonistically regulated | 34 |
recombinant single | 34 |
extreme physiological | 34 |
predispose pigs | 34 |
uniform probes | 34 |
aureus strain | 34 |
observation period | 34 |
tlr pathways | 34 |
oral cancer | 34 |
streptococcus pyogenes | 34 |
simulated heliox | 34 |
supplementation tended | 34 |
particularly important | 34 |
weaning period | 34 |
murine monocytic | 34 |
ms sera | 34 |
myelin sheets | 34 |
certain seroimmunological | 34 |
revealed five | 34 |
exhibited similar | 34 |
genus dermatophagoides | 34 |
significantly downregulated | 34 |
borrelia spirochetes | 34 |
new distinct | 34 |
full breath | 34 |
stimulation assay | 34 |
better humoural | 34 |
selected ncoder | 34 |
mhc ii | 34 |
receiving long | 34 |
therefore modified | 34 |
construct based | 34 |
renal dysfunction | 34 |
bifidobacterium adolescentis | 34 |
acute primary | 34 |
cells upregulated | 34 |
expressed lower | 34 |
lymphocyte population | 34 |
condition characterized | 34 |
dcs compared | 34 |
matched healthy | 34 |
fungal signal | 34 |
conditions induced | 34 |
recurrent inflammation | 34 |
initiated project | 34 |
lactobacillus casei | 34 |
regular focal | 34 |
dna primed | 34 |
ncoder framework | 34 |
status might | 34 |
predicted fev | 34 |
associated molecules | 34 |
polysaccharide served | 34 |
sweden belongs | 34 |
skin lesions | 34 |
piglets throughout | 34 |
modulated according | 34 |
per dietary | 34 |
combined data | 34 |
autoimmune condition | 34 |
physiological stress | 34 |
hdm allergy | 34 |
unknown cause | 34 |
stress level | 34 |
around one | 34 |
diet supplemented | 34 |
also regarding | 34 |
significant expression | 34 |
tnf production | 34 |
one framework | 34 |
increasing evidence | 34 |
flora including | 34 |
nuclear receptor | 34 |
serotype pneumococcal | 34 |
atmosphere outside | 34 |
evaluated different | 34 |
strains typical | 34 |
providing sensitive | 34 |
secreted high | 34 |
caga igg | 34 |
tigr strain | 34 |
totally inhibited | 34 |
oral cavity | 34 |
clinical response | 34 |
identical genotypes | 34 |
immobilization strategies | 34 |
gg induced | 34 |
active isomer | 34 |
investigated serum | 34 |
threefold higher | 34 |
upregulated cd | 34 |
comparing patients | 34 |
array screen | 34 |
every weeks | 34 |
using abc | 34 |
fv antibody | 34 |
data presented | 34 |
median values | 34 |
mapping revealed | 34 |
diabetic vascular | 34 |
mild self | 34 |
affects almost | 34 |
higher abca | 34 |
inflammation involving | 34 |
disease relapse | 34 |
mean time | 34 |
lactate dehydrogenase | 34 |
chamber served | 34 |
inhibited hsv | 34 |
cpg dna | 34 |
certain colorectal | 34 |
either ifn | 34 |
normal skin | 34 |
pneumococci produce | 34 |
patients lacking | 34 |
nodes demonstrated | 34 |
lipid homeostasis | 34 |
competent regulatory | 34 |
urea concentrations | 34 |
epithelial tissues | 34 |
computer program | 34 |
native der | 34 |
lethal amount | 34 |
percent predicted | 34 |
clinical gvhd | 34 |
corresponding recombinant | 34 |
aerococcus viridans | 34 |
solid support | 34 |
displayed properties | 34 |
key lysine | 34 |
successfully applied | 34 |
cell grafts | 34 |
immunological characteristics | 34 |
mt decreased | 34 |
driven primarily | 34 |
mt correlates | 34 |
supplementation improved | 34 |
different coupling | 34 |
exhibited considerable | 34 |
strains weak | 34 |
designated mala | 34 |
epithelial layers | 34 |
protein purification | 34 |
peptides corresponding | 34 |
another assay | 34 |
different commensal | 34 |
improve diseases | 34 |
complexes activate | 34 |
lowered risk | 34 |
former study | 34 |
signalling molecule | 34 |
resonance analysis | 34 |
directly applied | 34 |
mediated inflammatory | 34 |
gg compared | 34 |
serotype pneumococci | 34 |
stricto genospecies | 34 |
heliox saturation | 34 |
optimal stimulation | 34 |
lower risk | 34 |
less proliferating | 34 |
ms incidence | 34 |
often decreases | 34 |
specific mutation | 34 |
inhibitor factor | 34 |
increased cell | 34 |
without mala | 34 |
obtained sequentially | 34 |
results demonstrates | 34 |
heterohybridoma technique | 34 |
using standard | 34 |
degradation processes | 34 |
detailed status | 34 |
roughly corresponding | 34 |
results may | 34 |
monocytes produced | 34 |
anticancer immunity | 34 |
may point | 34 |
either seretide | 34 |
docking site | 34 |
studies indicated | 34 |
selected strains | 34 |
therapeutic approach | 34 |
without iga | 34 |
vitro analyses | 34 |
responses peaked | 34 |
findings may | 34 |
using different | 34 |
exact mechanisms | 34 |
antitumour effects | 34 |
using non | 34 |
postoperative infection | 34 |
human vaccination | 34 |
encephalitogenic peptide | 34 |
induce expression | 34 |
urea levels | 34 |
may account | 34 |
included sera | 34 |
reference surfaces | 34 |
activating immune | 34 |
standard statistical | 34 |
specialized laboratories | 34 |
via effects | 34 |
different probiotic | 34 |
within epithelial | 34 |
natural autoantibodies | 34 |
androgen receptor | 34 |
survival increases | 34 |
place high | 34 |
silico epitope | 34 |
growth arrest | 34 |
disulfide bond | 34 |
low preoperative | 34 |
generally low | 34 |
even higher | 34 |
human phagocytic | 34 |
higher estrogen | 34 |
mainly induced | 34 |
treatment tapered | 34 |
mg stay | 34 |
trigger proper | 34 |
resistance mechanisms | 34 |
microarrays providing | 34 |
lung carcinoma | 34 |
noncytopathic lymphocytic | 34 |
tlrs involved | 34 |
hapten oxazolone | 34 |
coli lipopolysaccharide | 34 |
identify lxrs | 34 |
involving skin | 34 |
remained unaltered | 34 |
subunit vaccine | 34 |
adhesion molecules | 34 |
effect remain | 34 |
vaccine coding | 34 |
wildtype target | 34 |
divers compared | 34 |
like cathepsin | 34 |
iga monoclonal | 34 |
nearly pure | 34 |
target antigens | 34 |
immunological responses | 34 |
putative igg | 34 |
becoming unresponsive | 34 |
often present | 34 |
glycosylation side | 34 |
hinge region | 34 |
supports used | 34 |
double kos | 34 |
induce measurable | 34 |
homologous wildtype | 34 |
falciparum malaria | 34 |
transcriptional regulators | 34 |
regarding genetic | 34 |
sites interleukin | 34 |
analogous complement | 34 |
dehydrated probes | 34 |
mg kg | 34 |
various cancer | 34 |
expression without | 34 |
oral epithelia | 34 |
responsiveness occurred | 34 |
kda plasmid | 34 |
eae development | 34 |
higher focus | 34 |
intestinal flora | 34 |
modulate cancer | 34 |
protein followed | 34 |
dna microarrays | 34 |
mutated resulting | 34 |
among strains | 34 |
littermate wildtype | 34 |
three masps | 34 |
disease atopic | 34 |
significantly better | 34 |
human vaccinees | 34 |
caga antibodies | 34 |
regulatory cytokines | 34 |
induce il | 34 |
standard assays | 34 |
synthetic peptides | 34 |
polarize differentially | 34 |
fully clarified | 34 |
research activity | 34 |
allergic individuals | 34 |
revealed immunologic | 34 |
genes specific | 34 |
opsonophagocytosis titer | 34 |
sex hormone | 34 |
increased superantigen | 34 |
neumoniae may | 34 |
pathogenesis remains | 34 |
salivary glands | 34 |
cytokines used | 34 |
choriocarcinoma cell | 34 |
lethally irradiated | 34 |
proper th | 34 |
unique protease | 34 |
borrelial evasion | 34 |
reduced il | 34 |
nonsignificant difference | 34 |
dysfunction may | 34 |
immunol doi | 34 |
directly responds | 34 |
maximum tnf | 34 |
cell function | 34 |
negative regulators | 34 |
cells proliferate | 34 |
hormone receptors | 34 |
molecular structures | 34 |
among many | 34 |
vascular lesions | 34 |
th treg | 34 |
fivefold increase | 34 |
effectively controlled | 34 |
mediated protection | 34 |
five commercially | 34 |
increased local | 34 |
higher androgen | 34 |
presented experimental | 34 |
affinity tag | 34 |
ics dose | 34 |
mounted hbsag | 34 |
stress model | 34 |
cd abright | 34 |
structurally related | 34 |
covalent binding | 34 |
human cytokines | 34 |
mechanisms underlying | 34 |
stable asthma | 34 |
ratio appeared | 34 |
phenotypic change | 34 |
five acutely | 34 |
multivariate regression | 34 |
may improve | 34 |
estimated cytotoxicity | 34 |
therapeutic cytokines | 34 |
similar adjuvant | 34 |
inhibited il | 34 |
activate dc | 34 |
malignant transformation | 34 |
bacteria induced | 34 |
injected i | 34 |
cytometric bead | 34 |
exposing bone | 34 |
i interferon | 34 |
immunomagnetic beads | 34 |
properties equal | 34 |
quantitative assays | 34 |
practically unresponsive | 34 |
ae assessed | 34 |
subsequent challenge | 34 |
general differences | 34 |
including breast | 34 |
differ predictably | 34 |
enzyme manganese | 34 |
curative treatment | 34 |
predominant subclass | 34 |
cd may | 34 |
distinct seroimmunological | 34 |
genetically constructed | 34 |
induced higher | 34 |
soluble hbsag | 34 |
atopic allergy | 34 |
cellular mechanisms | 34 |
blood drawn | 34 |
molecular mass | 34 |
also exist | 34 |
veillonella parvula | 34 |
recently initiated | 34 |
requiring fluticasone | 34 |
antiviral assays | 34 |
may indicate | 34 |
weaning compared | 34 |
host disease | 34 |
receptor decreased | 34 |
sensu stricto | 34 |
cells gained | 34 |
various times | 34 |
hbsag contains | 34 |
pneumococci equally | 34 |
recently generated | 34 |
deglycosylated recombinant | 34 |
saturation dive | 34 |
showed increased | 34 |
iga gene | 34 |
human iga | 34 |
anaphylactic reactions | 34 |
proteins used | 34 |
signal level | 34 |
simple nonradioactive | 34 |
international data | 34 |
vaccine preparations | 34 |
major type | 34 |
macroporous silicon | 34 |
functional genome | 34 |
whole molecule | 34 |
ml whole | 34 |
designated i | 34 |
high concentrations | 34 |
asthma exacerbated | 34 |
derived macrophages | 34 |
differentially activate | 34 |
ionic interactions | 34 |
will place | 34 |
epitopes present | 34 |
bacterial sonicate | 34 |
silicon coated | 34 |
reduced mhc | 34 |
total ige | 34 |
skin micro | 34 |
virus makes | 34 |
substantial differences | 34 |
unknown cofactor | 34 |
healthy human | 34 |
exhibit lowered | 34 |
previously shown | 34 |
surface mhc | 34 |
animals mounted | 34 |
single framework | 34 |
response peaked | 34 |
ldh release | 34 |
combining inhaled | 34 |
dramatically induced | 34 |
ssa compared | 34 |
may associate | 34 |
serotypes included | 34 |
isotype switching | 34 |
many others | 34 |
micro array | 34 |
undergoing periodic | 34 |
irradiated bacteria | 34 |
inhibited kb | 34 |
saccharamyces cerevisiae | 34 |
light microscope | 34 |
specific cellular | 34 |
epitope mapping | 34 |
stimulatory effect | 34 |
identify patients | 34 |
leading causes | 34 |
phagocytic cell | 34 |
divers indicate | 34 |
reporter gene | 34 |
binding lectinassociated | 34 |
one among | 34 |
signal intensity | 34 |
initial phase | 34 |
later evaluated | 34 |
dramatically increased | 34 |
lysine residues | 34 |
sensitivity reaction | 34 |
high ms | 34 |
vast majority | 34 |
interest recently | 34 |
without simultaneous | 34 |
revising standard | 33 |
significantly potentiated | 33 |
generated data | 33 |
earlier onset | 33 |
ae markedly | 33 |
length polymorphisms | 33 |
specific proliferation | 33 |
throughout one | 33 |
architecture ensures | 33 |
sentinel node | 33 |
epitheloid cells | 33 |
karolinska institutet | 33 |
bromide activation | 33 |
linked immunospot | 33 |
activation site | 33 |
last immunization | 33 |
patients expressed | 33 |
gtpbinding protein | 33 |
described affecting | 33 |
cell clonotypes | 33 |
inhibits apoptosis | 33 |
molecular repertoire | 33 |
induces development | 33 |
matched controls | 33 |
biological sample | 33 |
major cat | 33 |
disorder often | 33 |
induces cd | 33 |
analysis reveals | 33 |
binding strength | 33 |
translational modification | 33 |
individual experiment | 33 |
hours following | 33 |
protozoan trypanosoma | 33 |
cell cultures | 33 |
hlarestricted presentation | 33 |
domain shift | 33 |
mgl expression | 33 |
seventeen low | 33 |
much greater | 33 |
system providing | 33 |
human nk | 33 |
first crystal | 33 |
levels instead | 33 |
structural insight | 33 |
five domains | 33 |
ann performed | 33 |
bond isomers | 33 |
base involved | 33 |
normal functions | 33 |
optimized genes | 33 |
arginine deaminase | 33 |
clinical episodes | 33 |
adenosine receptors | 33 |
intestinal environment | 33 |
bacteria will | 33 |
markers associated | 33 |
node offers | 33 |
medical microbiology | 33 |
cycle duration | 33 |
containing molecule | 33 |
first appearance | 33 |
first demonstrate | 33 |
proliferative response | 33 |
soluble fraction | 33 |
recombinant ifn | 33 |
several references | 33 |
native rsa | 33 |
cell immunoglobulin | 33 |
cell degranulation | 33 |
neural networks | 33 |
specific poly | 33 |
antigens described | 33 |
total covering | 33 |
dependent enzyme | 33 |
measure intracellular | 33 |
malnutrition appears | 33 |
tb mortality | 33 |
conserved active | 33 |
charged arginine | 33 |
superfamily members | 33 |
abdominal diseases | 33 |
also selected | 33 |
derived lactobacilli | 33 |
increased spontaneous | 33 |
elisa binding | 33 |
managing laboratory | 33 |
recently established | 33 |
three individuals | 33 |
whereas svegfr | 33 |
membrane devices | 33 |
noncytolytic subset | 33 |
ro ssa | 33 |
double staining | 33 |
elisa method | 33 |
possibly decreased | 33 |
six times | 33 |
fractions using | 33 |
specific ifn | 33 |
make simultaneously | 33 |
i resulted | 33 |
endogenous nucleoside | 33 |
keeping track | 33 |
epitope identification | 33 |
matched peptides | 33 |
infiltrate psoriatic | 33 |
undergoing five | 33 |
vaccine candidates | 33 |
dimensional structure | 33 |
pha stimulation | 33 |
general scientific | 33 |
derive peptides | 33 |
mhc project | 33 |
lower doses | 33 |
positive inhabitants | 33 |
molecule isolated | 33 |
i stimuli | 33 |
fibrin depositions | 33 |
second generation | 33 |
significantly amplified | 33 |
binding data | 33 |
therefore analysed | 33 |
stain positive | 33 |
remaining seven | 33 |
gene families | 33 |
lacking antiviral | 33 |
supertype alleles | 33 |
wound healing | 33 |
provide new | 33 |
biological properties | 33 |
known peptide | 33 |
various species | 33 |
organizing information | 33 |
many contexts | 33 |
many relations | 33 |
twenty breast | 33 |
arthritic animals | 33 |
lipoprotein i | 33 |
two recombinant | 33 |
potential vaccine | 33 |
different proteins | 33 |
antigenpresenting cells | 33 |
chloride channels | 33 |
borderline responses | 33 |
colour flow | 33 |
erk pathways | 33 |
classically activated | 33 |
rich complexes | 33 |
directly induce | 33 |
complex samples | 33 |
greater proportion | 33 |
normoalbuminuria mg | 33 |
include components | 33 |
period prior | 33 |
confocal laser | 33 |
may recognize | 33 |
cell responsiveness | 33 |
small derived | 33 |
acquired antigen | 33 |
platelet cell | 33 |
cw binding | 33 |
profound impact | 33 |
separated cd | 33 |
two fractions | 33 |
producing msc | 33 |
potentially skew | 33 |
although children | 33 |
studies resulting | 33 |
icosl gene | 33 |
tumour regressors | 33 |
database represents | 33 |
including antimicrobial | 33 |
display low | 33 |
flanking introns | 33 |
neuroimmunology unit | 33 |
magnetic antibody | 33 |
samples will | 33 |
attractive fourth | 33 |
arthritogenic properties | 33 |
epitopes shared | 33 |
negative isolation | 33 |
dc subset | 33 |
cryopreserved human | 33 |
expressed significantly | 33 |
grade iii | 33 |
ige levels | 33 |
antagonisms towards | 33 |
automated manner | 33 |
used poisson | 33 |
isolation using | 33 |
perform comparative | 33 |
modality therapeutic | 33 |
established health | 33 |
assays applied | 33 |
overall infections | 33 |
almost potential | 33 |
guided mutagenesis | 33 |
boost immunizations | 33 |
matched tumour | 33 |
results form | 33 |
unmodified rsa | 33 |
human hla | 33 |
th dichotomy | 33 |
waldenstrom macroglobulinaemia | 33 |
tumourinfiltrating lymphocytes | 33 |
recognize keratin | 33 |
additional obstacle | 33 |
also prolongs | 33 |
animals challenged | 33 |
elicited induction | 33 |
pronounced growth | 33 |
malaria may | 33 |
another database | 33 |
work provides | 33 |
peptide mhc | 33 |
fractionation considerably | 33 |
detected lower | 33 |
arginase activity | 33 |
individuals responded | 33 |
tumour evolution | 33 |
surface maturation | 33 |
major strategic | 33 |
additional recently | 33 |
release remained | 33 |
coated pneumococci | 33 |
coexpress bdca | 33 |
effect modifier | 33 |
uncharged citrullin | 33 |
cell escape | 33 |
significant overall | 33 |
th conditions | 33 |
strains induced | 33 |
strong binders | 33 |
lactobacilli affect | 33 |
remained largely | 33 |
intravenous mtb | 33 |
complement proceeds | 33 |
modulate susceptibility | 33 |
termed mmgl | 33 |
radioactive immunoassays | 33 |
inactivated serum | 33 |
sensitive target | 33 |
mutation described | 33 |
system handles | 33 |
performed significantly | 33 |
first decade | 33 |
elicited comparable | 33 |
like reseptor | 33 |
causative coronavirus | 33 |
effects include | 33 |
regulatory cd | 33 |
antitumour immune | 33 |
large progressing | 33 |
versus diseased | 33 |
monocytes present | 33 |
associated immune | 33 |
pg ml | 33 |
cause malnutrition | 33 |
depends largely | 33 |
rational vaccine | 33 |
informative data | 33 |
infection will | 33 |
designed substrate | 33 |
map gene | 33 |
lactobacillus antibodies | 33 |
gpositive cells | 33 |
producing documentation | 33 |
whether bcl | 33 |
specific upregulation | 33 |
antibody characteristics | 33 |
lysing altered | 33 |
detect bcl | 33 |
cbps possess | 33 |
protein level | 33 |
clonal expansions | 33 |
strong il | 33 |
among tumourinfiltrating | 33 |
healthy versus | 33 |
break tolerance | 33 |
cd bdca | 33 |
database consists | 33 |
lectins represent | 33 |
based experiments | 33 |
possess innate | 33 |
microarray screenings | 33 |
origin compared | 33 |
native counterpart | 33 |
collagen type | 33 |
include increased | 33 |
expressing subset | 33 |
first generation | 33 |
significant systemic | 33 |
population expands | 33 |
dc represent | 33 |
dsrna helix | 33 |
potassium channels | 33 |
chain fv | 33 |
different species | 33 |
computerbased replacement | 33 |
will affect | 33 |
available database | 33 |
seven individuals | 33 |
factor xiiia | 33 |
elicit complement | 33 |
mutagenesis kit | 33 |
binding predictors | 33 |
two pss | 33 |
cdna prepared | 33 |
study involved | 33 |
assaying tumour | 33 |
antigenspecific th | 33 |
alternative carrier | 33 |
cell lymphoma | 33 |
major domains | 33 |
nucleotidyl transferases | 33 |
training performance | 33 |
paracasei strain | 33 |
homeostasis emerges | 33 |
eight danish | 33 |
sarcoid granulomas | 33 |
modulated expression | 33 |
imposed potentiation | 33 |
tcr repertoire | 33 |
protein selected | 33 |
system occurs | 33 |
specific abstracts | 33 |
derived murine | 33 |
diabetes complement | 33 |
approximately months | 33 |
established background | 33 |
stained paraffin | 33 |
towards comparing | 33 |
nonspecific immune | 33 |
rv infection | 33 |
nk lineage | 33 |
sensitivity allowing | 33 |
ml phytohemagglutinin | 33 |
controlling genes | 33 |
nd ika | 33 |
vaccine design | 33 |
multisystem granulomatous | 33 |
growth advantage | 33 |
polarizing capacity | 33 |
mg daily | 33 |
diseases caused | 33 |
now report | 33 |
nucleotidyl transfer | 33 |
helminth taenia | 33 |
therefore prove | 33 |
therefore enable | 33 |
multisite directed | 33 |
normal individuals | 33 |
vb gene | 33 |
wildtype cells | 33 |
reporter genes | 33 |
mycobacterial immunology | 33 |
earlier work | 33 |
taenia crassiceps | 33 |
qbcenriched networks | 33 |
driving capacities | 33 |
hypothesis examined | 33 |
sars survivors | 33 |
records simultaneously | 33 |
immunosorbent assays | 33 |
gland development | 33 |
stabilized blood | 33 |
proteomic maps | 33 |
terminal regions | 33 |
mammary epithelium | 33 |
coagulation factor | 33 |
edit records | 33 |
asthmatic individuals | 33 |
family history | 33 |
late progressors | 33 |
induces membrane | 33 |
coding regions | 33 |
fresh specimens | 33 |
lab differentially | 33 |
haematological cancers | 33 |
binding affinities | 33 |
daily research | 33 |
vitro bacterial | 33 |
cells cocultivated | 33 |
buffy coats | 33 |
engulfed bacteria | 33 |
magnetic beads | 33 |
advanced bioinformatics | 33 |
complex class | 33 |
siassi rzmail | 33 |
positive ae | 33 |
immunohistochemistry staining | 33 |
potent th | 33 |
citrullinated proteins | 33 |
gradual induction | 33 |
effects cbps | 33 |
mean percentage | 33 |
normal concentration | 33 |
global identification | 33 |
pasteur institute | 33 |
demonstrate spontaneously | 33 |
important effector | 33 |
conservative amino | 33 |
iterative development | 33 |
svegfr levels | 33 |
poor survival | 33 |
nk cytotoxicity | 33 |
nutritional status | 33 |
various strains | 33 |
autoantibodies directed | 33 |
broadly attractive | 33 |
sequential proteolytic | 33 |
inducing strain | 33 |
ika hospital | 33 |
specific iga | 33 |
laboratory data | 33 |
term haemodialysis | 33 |
unimmunized animals | 33 |
drawbacks linked | 33 |
human intestine | 33 |
granulomas consists | 33 |
turn activate | 33 |
malaria throughout | 33 |
exposed lipoproteins | 33 |
like structure | 33 |
urinary bladder | 33 |
costimulator ligand | 33 |
typical sarcoid | 33 |
binding potential | 33 |
protection induced | 33 |
wide spectrum | 33 |
status mg | 33 |
three structurally | 33 |
promoting function | 33 |
independent way | 33 |
immunity leads | 33 |
containing proteins | 33 |
human mhc | 33 |
endogenous amiloride | 33 |
translocating across | 33 |
also induces | 33 |
overall relationship | 33 |
major histocompatibility | 33 |
recombinant scfv | 33 |
related mblassociated | 33 |
stimulation led | 33 |
neutrophile cell | 33 |
immunoglobulin variable | 33 |
given subcutaneously | 33 |
associated antigen | 33 |
acid change | 33 |
eight exons | 33 |
macrophage culture | 33 |
beneficial effects | 33 |
histocompatibility complex | 33 |
tools may | 33 |
immunobioinformatics may | 33 |
hla interaction | 33 |
tumour area | 33 |
waz scores | 33 |
lab induced | 33 |
solution presented | 33 |
autologous monocytes | 33 |
dc caco | 33 |
ccf interacts | 33 |
vaccine formulation | 33 |
murine monoclonal | 33 |
saline served | 33 |
acceptor substrates | 33 |
based prime | 33 |
virtual committee | 33 |
mostly absent | 33 |
conserved fraction | 33 |
higher mrna | 33 |
specific cit | 33 |
gene level | 33 |
proteomic sequence | 33 |
using membrane | 33 |
ongoing immune | 33 |
measuring proliferation | 33 |
treated pneumococci | 33 |
gut maturation | 33 |
early complement | 33 |
quantifying total | 33 |
parent eph | 33 |
modified protein | 33 |
address nk | 33 |
designed antibody | 33 |
leptin receptor | 33 |
deficient type | 33 |
haz score | 33 |
dependent proliferation | 33 |
chronic state | 33 |
labelled cbp | 33 |
continued work | 33 |
dependent study | 33 |
sars vaccine | 33 |
cytotoxic activities | 33 |
adenosine levels | 33 |
pathogenesis require | 33 |
handles protein | 33 |
containing several | 33 |
special affinity | 33 |
alm dc | 33 |
full length | 33 |
human immature | 33 |
antigens within | 33 |
database provides | 33 |
various peptide | 33 |
adenosine receptor | 33 |
idiotypic antibody | 33 |
members indicates | 33 |
iapderived peptides | 33 |
molecular medicine | 33 |
inhibitory receptor | 33 |
rational approach | 33 |
various lab | 33 |
celldepleted bmt | 33 |
synthetase reveals | 33 |
five interrelated | 33 |
ficolins circulate | 33 |
will present | 33 |
also applied | 33 |
enhanced ifn | 33 |
allowing cytokines | 33 |
identified almost | 33 |
information content | 33 |
divergent tcr | 33 |
inflammation proceeds | 33 |
length sequenced | 33 |
dna induced | 33 |
simultaneously contact | 33 |
homologous prime | 33 |
first steps | 33 |
uncomplicated malaria | 33 |
kda invertebrate | 33 |
interuniversity institute | 33 |
response finding | 33 |
coelomic fluid | 33 |
strongly depended | 33 |
chimeric fusion | 33 |
macrophage antitumour | 33 |
cellular recognition | 33 |
blood cd | 33 |
induced significant | 33 |
signals involved | 33 |
bmodulated dc | 33 |
cells play | 33 |
also differentially | 33 |
quikchange multisite | 33 |
kenya continue | 33 |
nonenzymatic component | 33 |
immunomodulating effects | 33 |
research papers | 33 |
control assay | 33 |
suffer clinical | 33 |
loose sheets | 33 |
functional analogy | 33 |
bronchial biopsies | 33 |
peritumoural injection | 33 |
splenic barrier | 33 |
immune network | 33 |
antibody isolated | 33 |
induce tumour | 33 |
incidence rate | 33 |
sequences directly | 33 |
multiple first | 33 |
cell ifn | 33 |
molecularly distinct | 33 |
jnk sapk | 33 |
two major | 33 |
sectional surveys | 33 |
scientific discipline | 33 |
epithelial apoptosis | 33 |
strain caused | 33 |
identified markers | 33 |
exclusion chromatography | 33 |
human origin | 33 |
defined three | 33 |
selecting informative | 33 |
often affecting | 33 |
among tumours | 33 |
bacteria translocating | 33 |
applied point | 33 |
immunotherapy represents | 33 |
bronchial mucosa | 33 |
cat allergen | 33 |
first years | 33 |
candidate epitopes | 33 |
mhc molecules | 33 |
immunotherapeutic trials | 33 |
filemaker pro | 33 |
hokland department | 33 |
nonpsoriatic individuals | 33 |
share five | 33 |
software filemaker | 33 |
anticytokine antibody | 33 |
conserved catalytic | 33 |
experiment setups | 33 |
response rates | 33 |
nucleoside adenosine | 33 |
health effects | 33 |
antigens resulted | 33 |
develop multiple | 33 |
anthropometric measurements | 33 |
pcr technique | 33 |
detected specifically | 33 |
specific immunity | 33 |
seretide salmeterol | 33 |
rearrangement leading | 33 |
flanders interuniversity | 33 |
mbl showed | 33 |
possible associations | 33 |
modification catalysed | 33 |
brdu antibody | 33 |
sequence information | 33 |
enhancing immunity | 33 |
highly pure | 33 |
molecular mimicry | 33 |
may serve | 33 |
tumour antigens | 33 |
cells implies | 33 |
protein probes | 33 |
monocytederived dendritic | 33 |
cr release | 33 |
chip stability | 33 |
cadependent manner | 33 |